CLAIMS

1. A liquid pharmaceutical formulation comprising an antibody as active ingredient at a concentration of ~~200~~ 220 to 400 mg/ml and acetate.
2. The liquid pharmaceutical formulation of claim 1 comprising acetate at a concentration of 20 to 150 mM.
3. The liquid pharmaceutical formulation of claim 1 or 2 comprising glycine at a concentration of 100 to 500 mM.
4. The liquid pharmaceutical formulation of claims 1, 2 or 3 having an osmolality of 250 to 550 mOsm/kg.
5. The liquid pharmaceutical formulation of any one of claims 1 to 4 having a viscosity of equal or less than 110 mPa s.
6. The liquid pharmaceutical formulation of any one of claims 1 to 5 having a pH of 4.0 to 7.0.
7. The liquid pharmaceutical formulation of any one of claims 1 to 6 comprising NaCl at a concentration of 0 to 100 mM.
8. The liquid pharmaceutical formulation of any one of claims 1 to 7 comprising a surfactant, preferably Polysorbate 80.
9. The liquid pharmaceutical formulation of claim 7 wherein the surfactant is polysorbate 80 at a concentration of 0.001 to 0.03% w/v.
10. The liquid pharmaceutical formulation of any one of claims 1 to 9 characterized in that it does not comprise $MgCl_2$ or $CaCl_2$.
11. The liquid pharmaceutical formulation of any one of claims 1 to 10 wherein the antibody is epratuzumab.
12. A container containing the liquid pharmaceutical formulation according to any one of claims 1 to 11.
13. A kit containing the container of claim 12 and instructions for use.
14. A method for reducing the viscosity of a liquid pharmaceutical formulation containing a protein or an antibody at a concentration of 220 to 400 mg/ml, the method comprising

    a) providing the liquid pharmaceutical formulation, and

    b) adding acetate to a final concentration of 20 to 150 mM,

    wherein the viscosity of the liquid pharmaceutical formulation is reduced as compared to the same liquid pharmaceutical formulation without acetate.